Point 5.2.1 of Annex II to Regulation (EC) No 1107/2009 sets out the criteria for considering active substances that are micro-organisms as low-risk active substances and currently refers to the possible occurrence of multiple resistance to antimicrobials. Without any reference to the possibility of this resistance to be transferred, these criteria refer to the number of treatment options with antimicrobials which are effective against the active substance that is a micro-organism. Indeed, although micro-organisms can only be approved if not pathogenic, not infective under the recommended conditions of use, and not infective to humans under any circumstances if they are viruses, it is necessary to ensure that several treatment options with effective antimicrobials are available in order to maintain a high level of protection of human health in the unlikely event of an opportunistic infection, especially in vulnerable groups of the population. However, the possible occurrence of multiple resistance to some antimicrobials as currently outlined in point 5.2.1 does not clarify the number of effective treatment options based on antimicrobials which are available. It is therefore appropriate to specify the low-risk criteria applying for micro-organisms other than viruses. For the sake of clarity and legal certainty, it is therefore appropriate to further specify the criteria to consider an active substance that is a micro-organism as low-risk active substance, by referring to the number of antimicrobial agents against which the micro-organism is demonstrated susceptible. In addition, it is appropriate to specify that such criteria apply only for micro-organisms other than viruses, since viruses are usually provided with a narrow host range, and viruses which are infective to humans would be excluded from approval.
Recital 11, Regulation (EU) 2022/1438
In forcesince 31 Aug 2022